No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
HUN240719C22000
- 0.75
- +0.45+150.00%
15min DelayClose Jul 11 16:00 ET
0.75High0.75Low
0.75Open0.30Pre Close1 Volume111 Open Interest22.00Strike Price75.00Turnover27.43%IV0.71%PremiumJul 19, 2024Expiry Date0.59Intrinsic Value100Multiplier8DDays to Expiry0.16Extrinsic Value100Contract SizeAmericanOptions Type0.7574Delta0.3397Gamma30.12Leverage Ratio-0.0206Theta0.0036Rho22.81Eff Leverage0.0105Vega
Intraday
- 5D
- Daily
News
Express News | Wells Fargo Maintains Overweight on Huntsman, Lowers Price Target to $28
Express News | Huntsman Corp : BofA Global Research Cuts Price Objective to $27 From $29
Express News | Huntsman Corp : Wells Fargo Cuts Target Price to $28 From $32
Huntsman to Discuss Second Quarter 2024 Results on August 6, 2024
Huntsman Corporation (NYSE: HUN) will hold a conference call on Tuesday, August 6, 2024, at 10:00 a.m. ET to discuss its second quarter 2024...
Wells Fargo Maintains Huntsman(HUN.US) With Buy Rating, Cuts Target Price to $28
Wells Fargo analyst Michael Sison maintains $Huntsman(HUN.US)$ with a buy rating, and adjusts the target price from $32 to $28.According to TipRanks data, the analyst has a success rate of 53.2% and
A Glimpse Into The Expert Outlook On Huntsman Through 4 Analysts
Ratings for Huntsman (NYSE:HUN) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.The following table summarizes their recent ratings,
Comments
Despite low growth, undervalued Huntsman shares might be a good investment. However, the company's financial health is also key to consider. Its future outlook is possibly not fully reflected yet, offering a potentially attractive opportunity.
Should You Investigate Huntsman Corporation (NYSE:HUN) At US$24.82?Huntsman's low P/S ratio is down to limited revenue growth predictions. Failure to increase its revenue might keep its share price low and possibly lower P/S levels.
Huntsman's stagnant business growth, marked by a declining ROCE and stable capital employed, dampens its investment appeal despite a robust 43% stock return over five years.
Gapping up
In reaction to earnings/guidance:
• $Bowlero(BOWL.US$ +3.4%
Other news:
• $Intellia Therapeutics(NTLA.US$ +10.8% (Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002)
• $Gogo Inc(GOGO.US$ +5% (Repurchases 1.5 million shares of common stock from BlackRock)
• $ADC Therapeutics(ADCT.US$ +2.9% (ADC Therapeutics and Swedish Orphan Biovitrum AB (BIOVF) confirms positive CHM...
In reaction to earnings/guidance:
• $Bowlero(BOWL.US$ +3.4%
Other news:
• $Intellia Therapeutics(NTLA.US$ +10.8% (Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002)
• $Gogo Inc(GOGO.US$ +5% (Repurchases 1.5 million shares of common stock from BlackRock)
• $ADC Therapeutics(ADCT.US$ +2.9% (ADC Therapeutics and Swedish Orphan Biovitrum AB (BIOVF) confirms positive CHM...
13
Gainers:
• $National Vision(EYE.US$ +13.8% (appointed to join S&P SmallCap 600)
• $Braze(BRZE.US$ +12.2% (In reaction to earnings/guidance)
• $Oracle(ORCL.US$ +11.7% (In reaction to earnings/guidance)
• $TeraWulf(WULF.US$ +7.5% (announced recent financing actions and near-term ramp of digital infrastructure)
• $Continental Resources(CLR.US$ +7.5% (announces receipt of "take private" proposal from Hamm Family of $70/share)
•...
• $National Vision(EYE.US$ +13.8% (appointed to join S&P SmallCap 600)
• $Braze(BRZE.US$ +12.2% (In reaction to earnings/guidance)
• $Oracle(ORCL.US$ +11.7% (In reaction to earnings/guidance)
• $TeraWulf(WULF.US$ +7.5% (announced recent financing actions and near-term ramp of digital infrastructure)
• $Continental Resources(CLR.US$ +7.5% (announces receipt of "take private" proposal from Hamm Family of $70/share)
•...
8
4
Read more